阿斯利康股价下跌,20亿美元购入肿瘤学选择权
· gurufocus.com
阿斯利康(AZN),这家专注于肿瘤和罕见病的制药商,承诺向Summit Therapeutics新发行的股权投入20亿美元,同时进行临床合作。
AstraZeneca AZN, the oncology and rare-disease drugmaker, committed $2 billion to newly issued Summit Therapeutics equity alongside a clinical collaboration, wh...